System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Review Ppublish 4 citations

PubMed: 40202895 DOI: 10.1099/jgv.0.002095

Recent advances in the prevention and treatment of respiratory syncytial virus disease.

J Gen Virol 106(4)

Authors: Alexandra Sanchez-Martinez, Tom Moore, Telma Sancheira Freitas, Tami R Benzaken, Shaun O'Hagan, Emma Millar, Helen E Groves, Simon B Drysdale, Lindsay Broadbent

Affiliations

  • School of Biosciences, Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK.
  • Medical Radiation Physics Group, The National Physical Laboratory, Teddington, UK.
  • School of Mathematics and Physics, Faculty of Engineering and Physical Sciences, University of Surrey, Guildford, UK.
  • Immunisations and Vaccine Preventable Disease Division, United Kingdom Health Security Agency, London, UK.
  • Department of Paediatric Infectious Diseases, Royal Belfast Hospital for Sick Children, 274 Grosvenor Rd, Belfast, BT12 6BA, UK.
  • Acute Paediatric Medical Services, Antrim Area Hospital, Bush Road, Antrim, BT41 2RL, UK.
  • Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, 97 Lisburn Road, Belfast, BT9 7BL, UK.
  • Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
  • The NIHR Oxford Biomedical Research Centre, Oxford, UK.

Abstract

Respiratory syncytial virus (RSV) is associated with considerable healthcare burden; as such, prevention and treatment of RSV have long been considered a priority. Historic failures in RSV vaccine development had slowed the research field. However, the discovery of the conformational change in the RSV fusion protein (F) has led to considerable advancements in the field. The RSV pharmaceutical landscape has drastically changed in recent years with successful trials of both vaccines and second-generation mAbs leading to licensing and roll-out of these agents in several countries. RSV preventative and therapeutic measures will likely have a significant impact on RSV-related morbidity and mortality. However, there are still gaps in the protection that these immunizations offer that should be addressed. Many unanswered questions about RSV infection dynamics and subsequent disease should be a focus of ongoing research. This review discusses the currently licensed RSV pharmaceuticals and others that have recently progressed to clinical trials.

MeSH

Respiratory Syncytial Viruses, Vaccines, Pharmaceutical Preparations, Viruses, Research, Therapeutics, Antiviral Agents, Virus Diseases